Pharmaresearch Makes Strategic Investment in Drug Development Company Conext

Securing Commercialization Rights for 'CNT201'

On March 3, Pharmaresearch announced that it has signed a strategic investment agreement with the bio-venture company Conext, establishing a mid- to long-term partnership.

Pharmaresearch and Conext employees. Pharmaresearch

Conext is a venture company developing biopharmaceuticals based on protein recombination research and development as well as process technology. Previously, Pharmaresearch signed a licensing-in agreement regarding 'CNT201,' Conext's core pipeline and a new drug candidate.

CNT201 is a biopharmaceutical with the potential to expand into a wide range of indications, from aesthetic areas such as cellulite, Dupuytren's contracture, and Peyronie's disease, to therapeutic applications. Recently, Phase 1 clinical trials were completed with the U.S. Food and Drug Administration (FDA), and Phase 2 trials are currently underway.

Through this investment, Pharmaresearch has secured broad commercialization rights for 'CNT201.' The company also plans to actively pursue business collaborations based on Conext's technology. In addition, Pharmaresearch aims to promote an open innovation model for the development of various biopharmaceuticals.

A Pharmaresearch representative stated, "With this investment as a catalyst, the two companies will collaborate even more closely to accelerate the commercial success of CNT201 and the development of next-generation pipelines."

This content was produced with the assistance of AI translation services.